NPM1 gene mutations are present in 30% of all AML patients and in 50% of those with CN.29 Several studies have shown a favorable impact of NPM1-mutated (NPM1mut) on clinical outcome in the CN-AML setting.20,29 Nevertheless, a substantial proportion of patients with NPM1 mutations will eventually experience a disease recurrence. The gene discussed is NPM1; the disease is acute myeloid leukemia.